This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2019 Jul 4;381(1):86-88.

doi: 10.1056/NEJMe1906666.

A First Step toward a New Approach to Treating Membranous Nephropathy

Piero Ruggenenti¹, Giuseppe Remuzzi¹

Affiliations

Affiliation

¹ From Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII (P.R.) and Istituto di Ricerche Farmacologiche Mario Negri IRCCS (G.R.) - both in Bergamo, Italy.

PMID: 31269372
DOI: 10.1056/NEJMe1906666

Editorial

A First Step toward a New Approach to Treating Membranous Nephropathy

Piero Ruggenenti et al. N Engl J Med. 2019.

. 2019 Jul 4;381(1):86-88.

doi: 10.1056/NEJMe1906666.

Authors

Piero Ruggenenti¹, Giuseppe Remuzzi¹

Affiliation

¹ From Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII (P.R.) and Istituto di Ricerche Farmacologiche Mario Negri IRCCS (G.R.) - both in Bergamo, Italy.

PMID: 31269372
DOI: 10.1056/NEJMe1906666

No abstract available

PubMed Disclaimer

Comment on

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators. Fervenza FC, et al. N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427. N Engl J Med. 2019. PMID: 31269364 Clinical Trial.

Similar articles

[Membranous nephropathy: New insights in therapeutic approach].
Dahan K. Dahan K. Nephrol Ther. 2017 Apr;13 Suppl 1:S83-S87. doi: 10.1016/j.nephro.2017.02.002. Nephrol Ther. 2017. PMID: 28577748 French.
Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R, Eldin KW, Beck LH Jr, Michael M. Malatesta-Muncher R, et al. Pediatr Nephrol. 2018 Jun;33(6):1089-1092. doi: 10.1007/s00467-018-3923-5. Epub 2018 Mar 15. Pediatr Nephrol. 2018. PMID: 29546599
Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.
Delafosse M, Ponlot E, Esteve E, Ghislain L, Hanset N, Boffa JJ, Johanet C, Dahan K. Delafosse M, et al. Kidney Int. 2021 Apr;99(4):1023-1024. doi: 10.1016/j.kint.2020.12.029. Kidney Int. 2021. PMID: 33745532 No abstract available.
Pharmacological treatment of primary membranous nephropathy in 2016.
van de Logt AE, Hofstra JM, Wetzels JF. van de Logt AE, et al. Expert Rev Clin Pharmacol. 2016 Nov;9(11):1463-1478. doi: 10.1080/17512433.2016.1225497. Epub 2016 Sep 16. Expert Rev Clin Pharmacol. 2016. PMID: 27535699 Review.
[Membranous nephropathy: Diagnosis, new insights in pathophysiology, and therapeutic approach].
Dahan K. Dahan K. Rev Med Interne. 2016 Oct;37(10):674-679. doi: 10.1016/j.revmed.2016.02.003. Epub 2016 May 25. Rev Med Interne. 2016. PMID: 27236434 Review. French.

See all similar articles

Cited by

The Role of PLA2R in Primary Membranous Nephropathy: Do We Still Need a Kidney Biopsy?
McDonnell T, Wu HHL, Sinha S, Chinnadurai R. McDonnell T, et al. Genes (Basel). 2023 Jun 26;14(7):1343. doi: 10.3390/genes14071343. Genes (Basel). 2023. PMID: 37510247 Free PMC article. Review.
Salvianolic acid B attenuates membranous nephropathy by activating renal autophagy via microRNA-145-5p/phosphatidylinositol 3-kinase/AKT pathway.
Chen J, Hu Q, Luo Y, Luo L, Lin H, Chen D, Xu Y, Liu B, He Y, Liang C, Liu Y, Zhou J, Wu J. Chen J, et al. Bioengineered. 2022 May;13(5):13956-13969. doi: 10.1080/21655979.2022.2083822. Bioengineered. 2022. PMID: 35723058 Free PMC article.
Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort.
Gao S, Cui Z, Wang X, Zhang YM, Wang F, Cheng XY, Meng LQ, Zhou FD, Liu G, Zhao MH. Gao S, et al. Front Med (Lausanne). 2021 May 20;8:663680. doi: 10.3389/fmed.2021.663680. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34095173 Free PMC article.
Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report.
Caroli A, Remuzzi A, Ruggiero B, Carrara C, Rizzo P, Brambilla P, Ruggenenti P, Remuzzi G. Caroli A, et al. Kidney Med. 2020 Oct 23;2(6):804-809. doi: 10.1016/j.xkme.2020.07.008. eCollection 2020 Nov-Dec. Kidney Med. 2020. PMID: 33319205 Free PMC article.
Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood.
Mastrangelo A, Serafinelli J, Giani M, Montini G. Mastrangelo A, et al. Front Pediatr. 2020 May 12;8:205. doi: 10.3389/fped.2020.00205. eCollection 2020. Front Pediatr. 2020. PMID: 32478016 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.